Form 4: Olema Pharmaceuticals Director Granted Stock Options Valued at $4.08 Per Share

Olema Pharmaceuticals, Inc. Director Cynthia M. Butitta was granted 24,150 stock options with an exercise price of $4.08 per share, vesting over 12 months.

Summary

• Cynthia M. Butitta, a Director of Olema Pharmaceuticals, Inc. (OLMA), was granted 24,150 stock options.
• The stock options have an exercise price of $4.08 per share.
• The transaction date for the option grant was June 11, 2025.
• The options begin vesting on June 11, 2025, and will vest in 12 successive equal monthly installments.
• Full vesting is also triggered on the date of the Issuer's next annual meeting of stockholders if not fully vested by then, subject to continuous service.
• The expiration date for these stock options is June 11, 2035.

Sentiment

Score: 6

Explanation: Slightly positive, as it represents a standard compensation practice that aligns director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term performance and value creation.

Future Outlook

The vesting schedule of the stock options, extending over 12 months or until the next annual meeting, indicates an expectation of continued service from the director and aims to incentivize long-term commitment and performance.

Industry Context

The grant of stock options is a common form of equity compensation for directors in publicly traded companies, particularly within the biotechnology and pharmaceutical sectors, designed to attract and retain talent while aligning their financial interests with company performance and shareholder value.

Comparison to Industry Standards

• Equity compensation, such as stock options, is a standard practice for compensating non-employee directors across various industries, including biotechnology, to align their incentives with long-term shareholder value.
• The vesting schedule, typically over one to three years or tied to annual meetings, is also a common structure for such grants, similar to practices observed at comparable biotech firms like Moderna (MRNA) or BioNTech (BNTX) for their non-executive directors.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director constitutes a related party transaction, which is a standard and disclosed form of compensation for board members.

Stakeholder Impact

• Shareholders: The grant aims to align the director's financial interests with shareholder value creation, potentially leading to more favorable long-term outcomes.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The director's continued service is required for the options to vest according to the specified schedule.

Key Dates

Keywords

Olema Pharmaceuticals, OLMA, Stock Option Grant, Director Compensation, Insider Transaction, SEC Form 4, Equity Compensation